The earnings call for Alnylam Q2 2025 highlighted strong commercial performance and successful product launches, particularly for AMVUTTRA in ATTR-CM, leading to an upgraded financial outlook. Despite some decreases in collaboration revenue and product sales margins, the overall sentiment remains highly positive due to the robust growth and positive future guidance.

Company Guidance -

Q3 2025

During Alnylam's Q2 2025 earnings call, the company announced robust financial performance and upwardly revised guidance. Alnylam reported $672 million in total net product revenues, marking a 64% year-over-year increase, driven by the TTR franchise's $544 million revenue, which grew by 77% year-over-year. The launch of AMVUTTRA for ATTR-CM was a significant contributor, with approximately 1,400 patients on therapy as of June 30, generating an estimated $150 million in revenue. Consequently, Alnylam raised its 2025 total net product revenues guidance from a range of $2.05 billion to $2.25 billion to a revised $2.65 billion to $2.8 billion, reflecting a $575 million increase, or 27% at the midpoint. The company also highlighted ongoing international expansions and advancements in its RNAi therapeutic pipeline, including the initiation of the TRITON-CM Phase III study for nucresiran and encouraging Phase I data for mivelsiran in Alzheimer's disease.

Exceptional Q2 Commercial Performance

Alnylam's Q2 commercial portfolio delivered $672 million in net product revenues, representing 64% year-over-year and 43% quarter-over-quarter growth. The U.S. TTR performance was the major driver of growth, particularly due to the ATTR-CM launch for AMVUTTRA.

Successful Launch of AMVUTTRA in ATTR-CM

In the first full quarter of the ATTR-CM launch, Alnylam reported $544 million in global net TTR product revenues, a 77% increase compared to Q2 2024. Approximately 1,400 cardiomyopathy patients were receiving AMVUTTRA, contributing an estimated $150 million in revenue.

Upgraded Financial Guidance

Alnylam increased its 2025 net product revenue guidance from a range of $2.05 billion to $2.25 billion to a revised range of $2.65 billion to $2.8 billion, representing a 27% increase at the midpoint.

FDA Fast Track Designation for Nucresiran

The FDA granted Fast Track Designation to nucresiran for ATTR-CM, enabling a more streamlined review process.

Global Expansion

AMVUTTRA has regulatory approvals in Europe, Japan, and Brazil, with launches in Germany and Japan unlocking access to more patients worldwide.

Alnylam Pharma (ALNY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALNY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	0.27 / -	-0.87	―	―	―
Jul 31, 2025	2025 (Q2)	-0.54 / -0.51	-0.13	-292.31% (-0.38)
May 01, 2025	2025 (Q1)	-0.89 / -0.44	-0.52	15.38% (+0.08)
Feb 13, 2025	2024 (Q4)	-0.59 / -0.65	-1.1	40.91% (+0.45)
Oct 31, 2024	2024 (Q3)	-0.92 / -0.87	1.15	-175.65% (-2.02)
Aug 01, 2024	2024 (Q2)	-1.07 / -0.13	-2.21	94.12% (+2.08)
May 02, 2024	2024 (Q1)	-1.12 / -0.52	-1.4	62.86% (+0.88)
Feb 15, 2024	2023 (Q4)	-1.19 / -1.10	-1.68	34.52% (+0.58)
Nov 02, 2023	2023 (Q3)	-1.45 / 1.15	-3.32	134.64% (+4.47)
Aug 03, 2023	2023 (Q2)	-1.51 / -2.21	-2.29	3.49% (+0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALNY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$339.80	$392.24	+15.43%
May 01, 2025	$263.24	$255.13	-3.08%
Feb 13, 2025	$265.96	$264.89	-0.40%
Oct 31, 2024	$281.49	$266.59	-5.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alnylam Pharmaceuticals (ALNY) report earnings?

Alnylam Pharmaceuticals (ALNY) is schdueled to report earning on Oct 23, 2025, Before Open (Confirmed).

What is Alnylam Pharmaceuticals (ALNY) earnings time?

Alnylam Pharmaceuticals (ALNY) earnings time is at Oct 23, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALNY EPS forecast?

ALNY EPS forecast for the fiscal quarter 2025 (Q3) is 0.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing